Here are relevant reports on : ai-breast-cancer-screening-market
-
Oncology Nutrition Market by Cancer Type (Head & Neck, Stomach & Gastrointestinal, Liver, Pancreatic, Esophageal, Lung, Breast, Blood) - Global Forecast to 2023
The global oncology nutrition market is expected to reach USD 2.21 Billion by 2023 from USD 1.46 Billion in 2018, at a CAGR of 8.7%. Factors such as shifting focus from parenteral to enteral nutrition, increasing incidence of cancer, growing demand for nutritional feeding in the homecare sector, rising number of patients being treated for malnutrition, and increasing quality of clinical research on nutritional interventions are driving the market growth. The prominent players in the oncology nutrition market are Abbott Laboratories (US), Nestle S.A. (Switzerland), Danone (France), Fresenius Kabi AG (Germany), and B. Braun Melsungen AG (Germany).
- Published: April 2018
- Price: $ 16000
- TOC Available:
-
Contract Research Organization (CRO) Services Market by Type (Early Phase, Clinical, Lab, Consulting), Therapeutic Area (Cancer (Breast, Lung), Infectious, Neurology, Vaccines), Modality (Small Molecules, Biologics, Biosimilars) - Global Forecast to 2030
The global contract research organization (CRO) services market, valued at US$79.10 billion in 2024, stood at US$84.61 billion in 2025 and is projected to advance at a resilient CAGR of 8.3% from 2025 to 2030, culminating in a forecasted valuation of US$125.95 billion by the end of the period. Factors such as the increasing complexity & the growing volume of trials; the rising focus on patient-centric clinical trials such as Decentralized Clinical trials (DCTs); and the flexibility of services offered by CROs are supporting the growth of this market.
- Published: September 2025
- Price: $ 7150
- TOC Available:
-
Anatomic Pathology Market by Product & Service (Instruments (Cell Processor, Microtome), Consumable, Histopathology, Cytopathology, Application (Disease Diagnosis (Cancer (Breast, Lung), End User (Hospital Laboratories), Region - Global Forecast to 2026
The global anatomic pathology market growth is primed to transition from $35.1 billion in 2021 to $49.1 billion by 2026, showcasing a strong CAGR of 7.0%. The growth of this market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on personalized medicine.
- Published: November 2021
- Price: $ 4950
- TOC Available:
-
Breast Cancer Liquid Biopsy Market by Circulating Biomarkers, Region, End User, Investments, Market Dynamics, Platform Comparison (NGS, PCR), Competitive Landscape (Acquisition, Mergers, Collaboration, Competitive technology) & Geography
The global breast cancer liquid biopsy market is projected to grow at a CAGR of 23.1%. Factors such as increasing prevalence of breast cancer, increasing preference for noninvasive procedures, initiatives undertaken by government and global health organizations, technological advancements to augment market revenues, rising emphasis on personalized medicine in clinical practice, and increased funding for liquid biopsy R&D are driving the growth of the breast cancer liquid biopsy market. The key players in the global breast cancer liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).
- Published: August 2018
- Price: $ 4950
- TOC Available:
-
Intraoperative Radiation Therapy Market Size, Share & Trends by Technology (Electron IORT, Brachytherapy), Products & Services (Accelerators, Treatment Planning system, Applicators, Afterloaders, Accessories), Application (Breast, Brain, Lung Cancer) & Region - Global Forecast to 2025
The global intraoperative radiation therapy market in terms of revenue was estimated to be worth USD 48 million in 2020 and is poised to reach USD 66 million by 2025, growing at a CAGR of 6.4% from 2020 to 2025. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: February 2021
- Price: $ 4950
- TOC Available:
-
European NGS Services Market by Technology (SBS, SBL, SMRT, Pyrosequencing), Application (Exome Sequencing, CHIP-Seq), End User (Pharmaceutical Companies, Hospital), Disease [Oncology (Prostate, Lung, & Breast Cancer), Rare Diseases) - Forecast to 2020
The NGS services market in Europe is expected to reach USD 1,152 Million by 2020 from USD 444 Million in 2015, at a CAGR of 21% from 2015 to 2020. Factors such as rising preference of NGS over other platforms; rapid and cost-efficient sequencing; rising prevalence of inherited diseases; application of genomics in drug discovery; growing prevalence of cancer and other malignant diseases; and partnerships among companies, R&D centers, and universities are expected to drive market growth. However, high dependence on grants for R&D, lack of analytics, and stringent reimbursement policies are likely to restrict the growth of this market to a certain extent.
- Published: October 2015
- Price: $ 4950
- TOC Available:
-
Top 10 Cellular Analysis Market by Technology (Imaging, PCR, Flow Cytometry, High-content Screening, Blotting, Spectrophotometry), Application (Stem Cell, Cancer, Tissue Engineering) & End User (Biotechnology, Research) - Global Forecast to 2021
The top 10 cellular analysis market is expected to reach USD 41.34 Billion by 2021 from USD 28.66 Billion in 2016, at a CAGR of 7.6% during the forecast period. Cellular analysis is used for cell identification, cell interaction, cell viability, cell proliferation, cell structure study, cell signaling/cell transduction, target identification & validation, cell counting, and quality control. Currently, cellular analysis technologies are used in various phases of the drug discovery process, cancer diagnosis (oncology), blood cell analysis, toxicity testing, personalized medicine, pathogen testing, and other applications.
- Published: January 2017
- Price: $ 4950
- TOC Available:
-
Theranostics Market by Product (Diagnostic imaging (PET, CT, MRI), Radiopharmaceuticals (Lu-177, Sm-153, Ra-223, I-131), Biomarker screening, Software), Application (Prostate Cancer, Bone metastasis), & Stakeholder Expectations - Global Forecast to 2028
The global theranostics market, valued at US$1.9 billion in 2022, stood at US$2.1 billion in 2023 and is projected to advance at a resilient CAGR of 15.5% from 2023 to 2028, culminating in a forecasted valuation of US$4.3 billion by the end of the period. Increasing establishment of hospitals, rising focus on targeted therapies, and introduction of novel theranostic approaches are expected to drive the market during the forecast period.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
U.S. Cervical Cancer Screening Market by Test Type (PAP, HPV), Kit Type (PAP, HPV), End User (Hospitals, Laboratories, Physicians’ Offices & Clinics) - Global Forecast to 2020
The global cervical cancer screening market was approximately $15 billion in 2014 and is estimated to grow at a CAGR of 7.0% to reach nearly $22 billion by 2020. PAP test is the largest segment of the global cervical cancer screening market. However, HPV/co-test will be the fastest-growing product segment during the forecast period.
- Published: March 2026
- Price: $ 4950
- TOC Available:
-
Home Healthcare Market by Product (Therapeutic, Testing, Screening, Monitoring, Mobility Care), Service (Nursing, Infusion Therapy, Rehabilitation, Palliative Care), Indication (Cancer, Diabetes, CVD, Respiratory, Wound Care) - Global Forecast to 2030
The global home healthcare market, valued at US$285.3 billion in 2024, stood at US$309.9 billion in 2025 and is projected to advance at a resilient CAGR of 8.9% from 2025 to 2030, culminating in a forecasted valuation of US$473.8 billion by the end of the period. This growth is driven by the rising elderly population, which is more prone to chronic conditions such as hypertension, diabetes, and cardiovascular diseases, increasing the need for ongoing care at home.
- Published: August 2025
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
